Jakub Tolar, MD, PhD
Professor and Director, Stem Cell Institute
Pediatric Blood and Marrow Transplant Physician
- Blood and Marrow Transplantation
- Pediatric Blood and Marrow Transplant
- Blood Disorders (Hematology -- Benign)
- Skin Cancer
- Journey Clinic -- Center for Pediatric Blood and Marrow Transplantation
Charles University, Prague, Czech Republic
University of Minnesota (Pediatrics)
University of Minnesota (Hematology/Oncology and Blood and Marrow Transplantation); University of Minnesota (PhD in Molecular, Cellular, Developmental Biology and Genetics)
Ph.D. in Molecular, Cellular, and Developmental Biology and Genetics, University of Minnesota
425 E River Rd
Minneapolis, MN 55455
MMC 366 Mayo
8366A (Campus Delivery Code)
420 Delaware St SE
Minneapolis, MN 55455
Dr. Tolar is originally from the Czech Republic, and received his medical education in Prague at the Charles University. In 1992, he came to the University of Minnesota, where he completed his PhD in Molecular, Cellular & Developmental Biology and Genetics. He is currently a professor in the Department of Pediatrics, Blood and Marrow Transplantation, the Edmund Wallace Tulloch & Anna Marie Tulloch Chair in Stem Cell Biology, Genetics & Genomics, and the Director of Stem Cell/Gene Therapies. He is a member of the graduate faculty of the Microbiology, Immunology and Cancer Biology (MICaB) Program, the Molecular, Cellular, and Developmental Biology and Genetics (MCDB&G) Program, and the Stem Cell Biology (SCB) Program.
Dr. Tolar has a clinical practice through the University of Minnesota Masonic Children's Hospital, and his interests include educating and mentoring new physicians.
Dr. Tolar is active in many professional societies, and is a strong advocate for cooperation and communication within the clinical and research communities.
Dr. Tolar's research focuses on finding new ways of treating children with lethal diseases - cancer, inborn errors of metabolism, and devastating genetic disorders - using stem cell transplantation. He is also looking for safer and more effective methods of repairing and using a patient's own cells in diseases such as epidermolysis bullosa, mucopolysaccharidosis type I (Hurler syndrome), Fanconi anemia, and dyskeratosis congenita. Additional research interests include: reducing the negative effects of stem cell transplantation (such as using mesenchymal stromal cells for graft-versus-host disease), creation and use of induced pluripotent stem cells, gene therapy using gene addition (with viral vectors and trasposons), or gene editing (with synthetic nucleases to repair genes).